Zhou Yanming, Wang Xiao, Chen Shi, Wang Shijie
Department of Surgery, First Affiliated Hospital of Xiamen University, Xiamen, China.
Front Oncol. 2024 Nov 15;14:1442256. doi: 10.3389/fonc.2024.1442256. eCollection 2024.
Pancreatic metastasis from renal cell carcinoma (PMRCC) is unusual and there is no consensus on its treatment. The present study aims to evaluate the clinical outcomes of surgical resection for PMRCC.
PubMed and Web of Science were searched for Eligible studies from January 1980 to January 2024. Individual-patient data were pooled.
A total of 436 participants were identified. The morbidity and 90-day mortality were 38.1% and 3.4%, respectively. Post-pancreatectomy recurrence occurred in 44.1% of the patients. The overall median survival was 116 months, with a 3-, 5- and 10-year survival rate of 85.3%, 76.6%, and 46.5% respectively. On univariate analysis, repeat metastasectomy was associated with a significantly better prognosis ( =0.003).
These data suggest that surgical resection is a safe and effective therapeutic option for PMRCC. Repeat metastasectomy is positively suggested for recurrent disease provided all metastases can be removed curatively.
https://www.crd.york.ac.uk/prospero/, identifier CRD42024525218.
肾细胞癌胰腺转移（PMRCC）较为罕见，其治疗尚无共识。本研究旨在评估PMRCC手术切除的临床疗效。
检索PubMed和Web of Science数据库，纳入1980年1月至2024年1月的合格研究。汇总个体患者数据。
共纳入436名参与者。发病率和90天死亡率分别为38.1%和3.4%。44.1%的患者胰腺切除术后复发。总体中位生存期为116个月，3年、5年和10年生存率分别为85.3%、76.6%和46.5%。单因素分析显示，再次转移灶切除术与显著更好的预后相关（P=0.003）。
这些数据表明，手术切除是PMRCC一种安全有效的治疗选择。对于复发性疾病，若所有转移灶均可根治性切除，则积极建议行再次转移灶切除术。
